Apotex, Inc. v. Daiichi Sankyo Co.

by Robins Kaplan LLP
Contact

Case Name: Apotex, Inc. v. Daiichi Sankyo Co., No. 12-cv-9295, 2014 U.S. Dist. LEXIS 3156 (N.D. Ill. Jan. 9, 2014) (Coleman, J.)

Drug Product and Patent(s)-in-Suit: Benicar® (olmesartan medoxomil); U.S. Patents Nos. 6,878,703 (“the ’703 patent”) and 5,616,599 (“the ’599 patent”)

Nature of the Case and Issue(s) Presented: Daiichi Sankyo holds an approved NDA for Benicar and listed the ’599 and ’703 patents in the FDA’s Orange Book in connection with its NDA. As against those patents, Mylan was the first to file an ANDA including a paragraph IV certification. Accordingly, Mylan is entitled to 180 days of market exclusivity regardless of whether it established that the Orange Book patents were invalid or not. The start of the 180-day exclusivity period can only be triggered by Mylan’s marketing of its generic drug (21 U.S.C. § 355(j)(5)(B)(iv))—or if a subsequent filer obtains a qualifying final judgment of invalidity or non-infringement, Mylan must begin marketing within 75 days or forfeit its exclusivity period (21 U.S.C. § 355(j)(5)(D)(i)(I)(bb)(AA)).

Prior to suing Mylan on the ’599 patent, Daiichi Sankyo statutorily disclaimed every claim of the ’703 patent pursuant to 35 U.S.C. § 253. Eventually the district court found that the ’599 patent was valid and that Mylan infringed it. Mylan never brought a declaratory judgment action regarding the disclaimed ’703 patent. Here, Apotex seeks a final judgment of invalidity or non-infringement regarding the ’703 patent in the hopes of compelling Mylan to begin marketing within 75 days or forfeiting its exclusivity period. Daiichi Sankyo moved to dismiss Apotex’s complaint for lack of subject-matter jurisdiction. The court granted Daiichi Sankyo’s motion.

Why Daiichi Sankyo Prevailed: Daiichi Sankyo moved to dismiss Apotex’s complaint arguing that there can be no justiciable dispute concerning a disclaimed patent. Apotex argued that because a judgment has never been entered stating that the ’703 patent is invalid, the ’703 patent prevents it from selling its competing generic version of the Benicar drug until the end of Mylan’s 180 day exclusivity period. The Federal Circuit, in interpreting the 2003 MMA Amendments has noted that “[i]f the first ANDA filer ‘parked’ its 180-day exclusivity under an agreement with the brand-name company, a subsequent ANDA filer could independently trigger the first filer’s exclusivity period through a declaratory judgment action leading to a final judgment of invalidity or non-infringement, thereby accelerating the second ANDA filer’s ability to market its drug.” But here, the court found that the ’703 does not create an independent barrier that deprives Apotex of an economic opportunity to compete. Once Daiichi Sankyo disclaimed the ’703 patent, it is as if the disclaimed claims never existed. Moreover, Daiichi Sankyo requested that the FDA de-list the ’703 patent from the FDA’s Orange Book on July 11, 2006, and it is unclear why the FDA has yet to actually remove the patent from the Orange Book. But that is not Daiichi Sankyo’s problem.

Daiichi Sankyo is not preventing the FDA from approving Apotex’s ANDA through any delay tactics or strategies similar to the NDA holder’s covenant not to sue. Moreover, all parties acknowledge that Daiichi Sankyo can never assert the ’703 patent against any ANDA filer or any entity as the patent no longer exists by virtue of its disclaimer.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robins Kaplan LLP | Attorney Advertising

Written by:

Robins Kaplan LLP
Contact
more
less

Robins Kaplan LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!